Gene Salkind has bought stock on 6 days since Sep 2019
Director at Upexi, Inc., and 2 other companies
SEC CIK 0001592481 · Filings on SEC.gov ↗
Gene Salkind's record
3 months after each buy, from the first price a copier could get.
4 buys since 2020 with 3 months of prices.
Companies
Every filing
6 filings since Jan 2020, newest first
Upexi, Inc.
Director
Upexi, Inc.
Director
Upexi, Inc.
Director and 10% owner
Upexi, Inc.
Director and 10% owner
Grove, Inc.
Director and 10% owner
Mobiquity Technologies, Inc.
Director and 10% owner
About Gene Salkind
Gene Salkind, M.D. is a 68-year-old neurosurgeon and corporate director who has practiced for over 35 years outside Philadelphia, PA. He earned a B.A. Cum Laude from the University of Pennsylvania in 1974 and his M.D. from the Lewis Katz School of Medicine in 1979, completing his neurosurgical residency as Chief Resident at the Hospital of the University of Pennsylvania in 1985.( Currently, he serves as Chief of Neurosurgery at Holy Redeemer Hospital, President of Bruno & Salkind MDs since 1985, and holds professorships at the Lewis Katz School of Medicine.(
Dr. Salkind is an experienced investor in pharmaceuticals and biotechnology, with past successes including Intuitive Surgical, Pharmacyclics (acquired by AbbVie for $250/share), and Centocor (acquired by Johnson & Johnson for $4.9 billion).( He currently serves as Independent Director at Upexi, Inc. (UPXI) since 2021 and a member of its audit committee, owning over 10% of the company's voting securities; recent trades include purchasing 50,000 shares on November 20, 2025, at $2.55/share and 20,243 shares on July 11, 2025, for ~$100,000.( His other board roles include Chairman of Mobiquity Technologies since 2019, Director at Cure Pharmaceutical Corp., Avenir Wellness Solutions, Coeptis Therapeutics Holdings, and Grove Holdings.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.